Evidence map›Paper›PMID 30410082›Full record

Trial reportBone marrow transplantation2019

Post-transplant immunotherapy with WT1-specific CTLs for high-risk acute myelogenous leukemia: a prospective clinical phase I/II trial.

Hee-Je Kim, Hyun-Jung Sohn, Jung-A Hong, Hyun-Joo Lee, Dae-Hee Sohn, Chang-Ae Shin, Hyun-Il Cho, Woo-Sung Min, Tai-Gyu Kim

Abstract readClinical Trial, Phase IClinical Trial, Phase IILetter
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Bone marrow transplantation, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Bacteria in neoplastic diseases: A brief note on Wilms tumor.World journal of experimental medicine · 2025
    Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Antigen Targets for the Development of Immunotherapies in Leukemia.International journal of molecular sciences · 2019
    Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Hee-Je KimLeukemia Research Institute, Seoul St. Mary's Hematology Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Hyun-Jung SohnCatholic Hematopoietic Stem Cell Bank, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Jung-A HongCatholic Hematopoietic Stem Cell Bank, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Hyun-Joo LeeCatholic Hematopoietic Stem Cell Bank, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Dae-Hee SohnDepartment of Microbiology, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Chang-Ae ShinDepartment of Microbiology, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Hyun-Il ChoCatholic Hematopoietic Stem Cell Bank, College of Medicine, The Catholic University of Korea, Seoul, Korea.ORCID http://orcid.org/0000-0002-6520-3066
Woo-Sung MinLeukemia Research Institute, Seoul St. Mary's Hematology Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Tai-Gyu KimCatholic Hematopoietic Stem Cell Bank, College of Medicine, The Catholic University of Korea, Seoul, Korea. kimtg@catholic.ac.kr.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AdultFemaleHumansImmunotherapyLeukemia, Myeloid, AcuteMaleMiddle AgedProspective StudiesT-Lymphocytes, Cytotoxic

Identifiers

PMID30410082
PMCPMC6760543

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.